Treatment of Primary Hepatic Diffuse Large B-Cell Lymphoma (DLBCL)
Primary hepatic lymphoma (PHL) is an uncommon presentation in which lymphoma arises within the liver. When histological assessment confirms diffuse large B-cell lymphoma (DLBCL) — the predominant subtype seen in this setting — the diagnosis directly determines the treatment pathway.
Clinical scenario
Confirmed diagnosis of primary hepatic diffuse large B-cell lymphoma (DLBCL). Treatment approach for PHL is guided by histology: DLBCL is managed primarily with systemic therapy, distinct from indolent subtypes which may be observed or treated with other modalities.
Treatment goal
Achieve complete response of the primary hepatic lymphoma, defined as a Deauville score of 1–2.
Treatment approach
Primary hepatic DLBCL is managed with systemic chemotherapy; an established combination regimen is most commonly employed as the first-line approach, with good disease control reported.
The complete regimen, sequencing, and eligibility criteria are available in the full structured protocol below.
References
DOI: 10.3389/fonc.2025.1475118
- The treatment approach to PHL is guided essentially by the disease histology, with diffuse large B-cell lymphomas (DLBCL) treated primarily with systemic therapy and indolent lymphomas treated with various modalities including observation, surgery or systemic therapy.
- DLBCL is the predominant histology observed among primary hepatic lymphomas.
- Primary hepatic DLBCL appears to be treated mostly with chemotherapy with good disease control.
- The most commonly used chemotherapy regimen was R-CHOP.
- Response was assessed by Deauville criteria with scores of 1–2 considered as complete response (CR) per institutional practice.
View source ↗